Low-risk differentiated thyroid cancer patients in the U. S. experience lower rates of mortality

NewsGuard 100/100 Score

A new study has shown that overall and cause-specific mortality rates in individuals in the U.S. with low-risk differentiated thyroid cancer (DTC) are low. The study is published in the peer-reviewed journal Thyroid®, the official journal of the American Thyroid Association® (ATA®). 

Cari Kitahara, PhD, from the National Cancer Institute, National Institutes of Health, and coauthors identified 51,854 individuals diagnosed with first primary DTC at low risk of recurrence and compared observed mortality rates in DTC patients with expected rates in the matched U.S. general population. Thyroid cancer accounted for only 4.3% of deaths. The most common causes of death were malignancies (other than thyroid cancer) and cardiovascular disease.

"In brief, we observed that these patients experienced lower rates of mortality overall and from most other causes compared with the general population, consistent with previous studies," stated the investigators. "Our study is unique, in that it was restricted to survivors of low-risk DTC and included all ages at diagnosis, a longer duration of follow-up compared with previous studies, and a comprehensive investigation of specific causes of death."

Journal reference:

TRAN, T.-V.-T., et al. (2024). All-Cause and Cause-Specific Mortality Among Low-Risk Differentiated Thyroid Cancer Survivors in the United States. Thyroid. doi.org/10.1089/thy.2023.0449.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI chatbots outperform doctors in empathy and readability for cancer-related questions, study finds